Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC

NCT07524257 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

494

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)
Metastatic NSCLC

Interventions

DRUG: Drug: Nogapendekin alfa inbakicept (NAI)
DRUG: Pembrolizumab
DRUG: Cisplatin or Carboplatin
DRUG: Nab-paclitaxel (squamous) OR Pemetrexed (nonsquamous)
DRUG: Nab-paclitaxel OR Paclitaxel OR Docetaxel (squamous)
DRUG: Pemetrexed (nonsquamous)

Sponsor

ImmunityBio, Inc.